A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells. [electronic resource]
Producer: 20150525Description: 4331-8 p. digitalISSN:- 2476-762X
- Acetylation
- Anilides -- pharmacokinetics
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Brain Neoplasms -- drug therapy
- Cell Division -- drug effects
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cyclin-Dependent Kinase Inhibitor p21 -- biosynthesis
- Drug Screening Assays, Antitumor
- G1 Phase Cell Cycle Checkpoints -- drug effects
- Glioma -- drug therapy
- Histone Deacetylase Inhibitors -- pharmacology
- Histone Deacetylases
- Histones -- metabolism
- Humans
- Hydroxamic Acids -- pharmacokinetics
- Lung Neoplasms -- drug therapy
- M Phase Cell Cycle Checkpoints -- drug effects
- Molecular Docking Simulation
- Repressor Proteins -- antagonists & inhibitors
- Tumor Suppressor Protein p53 -- biosynthesis
- Vorinostat
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.